CSL has received approval from the EC for Andembry (garadacimab) to prevent recurrent attacks of HAE in patients aged 12 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible resultsSome results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback